Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial
Eur J Heart Fail
.
2024 Apr 17.
doi: 10.1002/ejhf.3240.
Online ahead of print.
Authors
Rahul Aggarwal
1
,
Deepak L Bhatt
2
,
Michael Szarek
3
4
,
Lawrence A Leiter
5
,
Christopher P Cannon
1
,
Renato D Lopes
6
,
Michael J Davies
7
,
Phillip Banks
7
,
Bertram Pitt
8
,
Ph Gabriel Steg
9
10
Affiliations
1
Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
2
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
3
CPC Clinical Research and University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
4
State University of New York Downstate School of Public Health, Brooklyn, NY, USA.
5
Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
6
Duke University School of Medicine, Durham, NC, USA.
7
Lexicon Pharmaceuticals, Inc, The Woodlands, TX, USA.
8
University of Michigan, Ann Arbor, MI, USA.
9
Université Paris-Cité, INSERMU1148 and AP-HP Hopital Bichat, Paris, France.
10
French Alliance for Cardiovascular Trials, Paris, France.
PMID:
38629597
DOI:
10.1002/ejhf.3240
No abstract available
Grants and funding
Lexicon Pharmaceuticals